Thus, we next set up to pharmacologically or genetically inhibit NRF2 by examining ovarian cancer cells treated with either retinoid/rexinoid bexarotene or an NRF2 specific/targeting siRNA (Figure 3). This evidence concerns the gene NFE2L2 and ovarian carcinoma.